Hydroxychloroquine (HCQ) has been one of the most controversial drugs for COVID-19 treatment. Despite being greatly efficacious in treating malaria, the risk-benefit ratio of HCQ in treating COVID-19 is debatable. Amidst this uncertainty, the USFDA has recently warned against the use of this drug in patients with COVID-19. Considering the demand and outpatient use of hydroxychloroquine (HCQ) in patients with COVID-19, the FDA has warned healthcare professionals about the potential risks associated with HCQ and chloroquine (CQ).
The drugs are often prescribed in combination with azithromycin and other QT-prolonging medicines. The FDA has further clarified that HCQ and CQ have not yet proven to be safe and effective in treating or preventing COVID-19. Instead, studies have suggested that both these drugs can result in: QT interval prolongation Ventricular tachycardia Increased insulin…
